Evotec 2025 Outlook: Revenues To Grow 5%-10%, Reaching €840M-€880M (Vs. €879.457M Est.), Sees Adj. EBITDA Of €30M-€50M; For 2028 Outlook, Expects 8%-12% CAGR And An EBITDA Margin Above 20%

Benzinga
04-17

Guidance for full-year 2025

Group revenues expected in the range of € 840 - 880 m (2024: € 797.0 m)

R&D expenditures are expected in a range of € 40 - 50 m (2024: € 50.8 m)

Adjusted Group EBITDA is expected to reach € 30 - 50 m (2024: € 22.6 m)

Outlook 2028

Group revenues CAGR 2024-2028 targeted to be in a range of 8 - 12 %

Adj. EBITDA margin 2028 expected to be above 20 %

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10